Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results

Decision not based on safety concerns; Phase 3 lupus program continues as planned INDIANAPOLIS, Feb. 7, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will discontinue the Phase 3 rheumatoid arthritis (RA)...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news